TRANSPUPILLARY THERMOTHERAPY

Protocol: OPT019
Effective Date: August 1, 2017

Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>COMMERCIAL, MEDICAID AND MEDICARE COVERAGE RATIONALE</td>
<td>1</td>
</tr>
<tr>
<td>DESCRIPTION OF SERVICES</td>
<td>2</td>
</tr>
<tr>
<td>CLINICAL EVIDENCE</td>
<td>2</td>
</tr>
<tr>
<td>U.S. FOOD AND DRUG ADMINISTRATION (FDA)</td>
<td>6</td>
</tr>
<tr>
<td>APPLICABLE CODES</td>
<td>6</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>6</td>
</tr>
<tr>
<td>PROTOCOL HISTORY/REVISION INFORMATION</td>
<td>7</td>
</tr>
</tbody>
</table>

INSTRUCTIONS FOR USE

This protocol provides assistance in interpreting UnitedHealthcare benefit plans. When deciding coverage, the enrollee specific document must be referenced. The terms of an enrollee's document (e.g., Certificate of Coverage (COC) or Evidence of Coverage (EOC)) may differ greatly. In the event of a conflict, the enrollee's specific benefit document supersedes this protocol. All reviewers must first identify enrollee eligibility, any federal or state regulatory requirements and the plan benefit coverage prior to use of this Protocol. Other Protocols, Policies and Coverage Determination Guidelines may apply. UnitedHealthcare reserves the right, in its sole discretion, to modify its Protocols, Policies and Guidelines as necessary. This protocol is provided for informational purposes. It does not constitute medical advice. This policy does not govern Medicare Group Retiree members.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

COMMERCIAL, MEDICAID AND MEDICARE COVERAGE RATIONALE

Transpupillary thermotherapy is medically necessary for treating retinoblastoma and choroidal melanomas.

Transpupillary thermotherapy is not medically necessary for treating choroidal neovascularization or macular degeneration. Results of studies evaluating the use of transpupillary thermotherapy for the prevention or control of choroidal neovascularization lesions in patients with age-related macular degeneration (AMD) do not provide sufficient evidence to conclude that transpupillary thermotherapy improves loss of vision due to AMD.

Medicare does not have a National Coverage Determination (NCD) specifically for transpupillary thermotherapy used in the treatment of retinoblastoma or choroidal melanomas. Local Coverage Determinations (LCDs) for Nevada do not exist at this time. (Accessed June 2017)
For Medicare and Medicaid Determinations Related to States Outside of Nevada:
Please review Local Coverage Determinations that apply to other states outside of Nevada.
http://www.cms.hhs.gov/mcd/search

Important Note: Please also review local carrier Web sites in addition to the Medicare Coverage database on the Centers for Medicare and Medicaid Services’ Website.

DESCRIPTION OF SERVICES

Transpupillary thermotherapy (TTT) of CNV lesions due to age-related macular degeneration involves prolonged application of low-energy, infrared laser to areas of neovascularization thereby causing photocoagulation. The goal of TTT is to stop the growth and leakage of the new blood vessels, thereby preserving vision. Transpupillary thermotherapy has also been proposed to treat ocular tumors such as choroidal melanoma and retinoblastoma. The goal of TTT is to ablate cancerous masses by heating them to temperatures as high as 60 degrees Celsius. Healthy ocular tissue may also be damaged, but generally the damage is limited to the site of treatment.

CLINICAL EVIDENCE

Transpupillary Thermotherapy for Choroidal Melanomas
Chojniak et al. (2011) evaluated the efficacy of transpupillary thermotherapy (TTT) for the treatment of small choroidal melanomas. The study was a prospective nonrandomized study of transpupillary thermotherapy for small (thickness ≤ 4.0 mm and basal diameter ≤ 12 mm) pigmented choroidal melanomas presenting either growth or risk factors for growth and metastasis. Ophthalmoscopic aspect, tumor control, visual acuity and complications were evaluated. Twenty-seven patients were treated; mean age 61 years; mean tumor thickness before treatment was 2.7 mm and base was 8.52 mm. After a mean of three treatment sessions and 45-month follow-up, mean tumor thickness decreased significantly to 1.34 mm and mean tumor base to 5.48 mm. Complications were observed in 12 patients (44%) and included retinal vascular occlusion, optic disc atrophy, retinal traction, vitreous hemorrhage, rhegmatogenous retinal detachment, and maculopathy. Lesions touching the optic disc were associated with a significantly higher rate of disc atrophy after treatment (60% vs. 40%). Visual acuity remained the same in nine eyes (33%), improved in five (19%) and decreased during the first 6 months after treatment in 13 eyes (48%). Complete tumor control without recurrence was observed in 25 patients (93%). Recurrence at tumor margin was detected in two (7%). All eyes were preserved. One patient had tumor-related death. According to the investigators, TTT is an effective treatment in the management of selected small choroidal melanoma. Decrease in visual acuity occurred early after treatment, mainly as a complication of subfoveal and perifoveal tumor treatment.

Pilotto et al. (2009) compared long-term choroidal vascular changes after iodine-125 brachytherapy (IBT) versus transpupillary thermotherapy (TTT) used as primary treatment. A total of 95 small choroidal melanomas were randomized: 49 eyes with TTT and 46 eyes with IBT alone. Mean follow-up was 56.2 months. Tumor regressed in 45 (92%) TTT-treated vs 45 (98%) IBT-treated eyes. Four TTT-treated and one IBT-treated tumor recurred. Closure of medium and large choroidal vessels was observed in 17 (35%) TTT-treated vs 44 (96%) IBT-treated eyes. Choroidal vascular remodeling was detected in 20 (41%) TTT-treated and 16 (35%) IBT-treated eyes. Retinochoroidal anastomosis was present in 4 of the 37 (11%) TTT-treated eyes with patency of medium and large choroidal vessels, but
never observed in the IBT-treated eyes, and was associated with tumor recurrence. Among IBT-treated
eyes, segments of choroidal vascular wall ICG staining and choroidal aneurysmal changes were
detected in 30 (65%) and 7 (15%), respectively. These changes were never detected in TTT-treated
cases. The investigators concluded that the pattern of tumor choroidal vascular changes following IBT
and TTT differs. TTT is less effective in closing all tumor vasculature. The role of long-term choroidal
vascular remodeling observed after these two treatments needs longer follow-up.

Desjardins et al. (2006) conducted a randomized study to determine whether systematic TTT after
proton beam radiotherapy could have a beneficial effect in 151 patients with uveal melanomas. One
half of the patients received proton beam radiotherapy alone (and the other half received the same dose
of proton beam radiotherapy followed by TTT at 1, 6 and 12 months. The median follow-up was 38
months. The patients treated with TTT showed a greater reduction of tumor thickness, less retinal
detachment at the latest follow-up and a lower secondary enucleation rate. Further studies are needed
to determine whether TTT could be beneficial to smaller tumors and to define its optimal dose.

Mashayekhi et al. (2015) reported the long-term outcome of primary transpupillary thermotherapy
(TTT) for 391 patients with choroidal melanoma in a retrospective review of medical records. Of
391 patients, 311 (80%) were treated from 1995 to 2000 and 80 (20%) from 2001 to 2012. Kaplan-
Meier estimates for tumor recurrence in the 1995 to 2000 group were 29% at 5 years and 42% at 10
years, whereas estimates for tumor recurrence in the 2001-2012 group were 11% at 5 years and 15% at
10 years. Of 108 recurrent tumors 20 were controlled with additional TTT and 62 required plaque
radiation (n = 60) or proton beam radiation (n = 2), with enucleation necessary in 26 patients. Tumor
recurrence correlated with the number of high-risk tumor features: 10-year recurrence was 18% in
those with 1 or 2 risk factors, 35% in those with 3 to 5 factors, and 55% in those with 6 or 7 factors.
On multivariate analysis, features predictive of tumor recurrence were presence of symptoms, shorter
distance between the tumor and the optic disc, subretinal fluid, thickness of residual tumor scar, and
elevation of residual tumor scar. The only factor predictive of extraocular tumor extension was
intraocular tumor recurrence after TTT treated with additional TTT. Presence of orange pigment before
TTT, tumor recurrence, and extraocular tumor extension were predictive of distant metastasis. The
authors concluded that this study shows a direct correlation between a larger number of high-risk
tumor features and higher rates of tumor recurrence after primary TTT of (small) choroidal melanoma.
The authors recommend that when possible, small choroidal melanomas with multiple risk factors
should be treated with methods other than TTT. According to the authors, the impact of this new
diagnostic and prognostic modality on case selection for primary TTT of small choroidal melanocytic
tumors warrants further study.

**National Cancer Institute (NCI)**
The NCI states that transpupillary thermotherapy (TTT) has important limitations that confine its use
to very restricted circumstances. The limited ability of TTT to penetrate thick tumors with sufficient
energy restricts its use to small melanomas or tumors of a size that some ophthalmologists recommend
for follow-up without any initial therapy. When used as the primary therapy, there are relatively high
rates of local recurrence and retinal vascular damage. Recurrence rates are particularly high when the
tumor abuts the optic nerve and overhangs the optic disc. The NCI also states that combined therapy,
with ablative laser coagulation or transpupillary thermotherapy to supplement plaque treatment may be
used for medium-sized choroidal melanomas (NCI, Intraocular (Uveal) Melanoma 2015).
Transpupillary Thermotherapy for Retinoblastomas

Shields et al. (2005) evaluated the effectiveness of chemoreduction alone and chemoreduction with thermotherapy for macular retinoblastoma in a prospective, nonrandomized, single-center case series. There were 68 macular retinoblastomas in 62 eyes of 49 patients managed with chemoreduction. All patients received 6 cycles of intravenous chemoreduction using vincristine, etoposide, and carboplatin. The patients were then treated according to 1 of 2 approaches: chemoreduction alone with no adjuvant focal therapy (group A) or chemoreduction combined with adjuvant foveal-sparing thermotherapy to each macular retinoblastoma (group B). The main outcome measure was tumor recurrence. Of the 68 tumors, 28 were in group A and 40 were in group B. A comparison of both groups revealed that the tumors were similar with regard to clinical features. Following treatment, Kaplan-Meier estimates revealed that group A tumors showed recurrence in 25% by 1 year and 35% by 4 years whereas those in group B showed recurrence in 17% by 1 year and 17% by 4 years. By multivariate analysis, the most important factors predictive of tumor recurrence were smaller macular tumor size (judged by percentage of the macula occupied by the tumor), absence of subretinal or vitreous seeds, and unilateral disease. Tumors most destined for recurrence are small tumors. According to the investigators, treatment of macular retinoblastoma with chemoreduction plus adjuvant foveal-sparing thermotherapy provides tumor control of 83% by 4 years, and this is slightly more favorable than chemoreduction alone, which provides control of 65% by 4 years.

Shields et al. (1999) reported on the results of TTT in 188 retinoblastomas in 80 eyes of 58 patients in a prospective study. Smaller tumors were managed by thermotherapy alone; larger tumors were managed by chemoreduction, followed by tumor consolidation with thermotherapy. Complete tumor regression was achieved in 161 tumors (85.6%). A total of 27 tumors (14.4%) developed recurrence. The investigators concluded that thermotherapy is effective for relatively small retinoblastomas without associated vitreous or subretinal seeds. Such tumors are generally best managed by chemoreduction, followed by plaque brachytherapy or external beam irradiation. However, supplemental thermotherapy can often be employed in such cases if vitreal or subretinal seeds have resolved following irradiation. The study also concluded that larger tumors require more intense treatment than smaller tumors and are at greater risk of ocular complications, such as focal iris atrophy and focal paraxial lens opacity.

Abramson and Schefler (2004) evaluated 91 retinoblastoma tumors in 22 eyes of 24 patients with TTT as the primary treatment modality. In this case series, the outcome measures included local tumor recurrence and failure of TTT, requiring the use of salvage therapies. The mean follow-up from the time of the first TTT treatment was 21 months. Tumors were defined as cured when no regrowth had been observed for six months after treatment. A total of 84 tumors (92%) were cured with TTT alone and seven tumors (8%) required salvage treatments. All seven tumors requiring salvage treatment were cured without enucleation. The mean number of treatment sessions required for cure was 1.7, with 64% of the tumors requiring only one session. According to the investigators, retinoblastoma tumors less than 1.5 DD in base diameter can be successfully treated with TTT alone.

National Cancer Institute (NCI)

According to the NCI, laser therapy (thermotherapy) may be used as primary therapy for small retinoblastoma tumors or in combination with chemotherapy for larger retinoblastoma tumors. Traditional photocoagulation, in which the laser was applied around the tumor, has given way to thermotherapy. Thermotherapy is delivered directly to the tumor surface via infrared wavelengths of light (NCI, Retinoblastoma 2016).
Transpupillary Thermotherapy for Choroidal Neovascularization (CNV) Associated With Age-Related Macular Degeneration (AMD)

In a 24-month, double-masked, randomized, active-controlled clinical trial, Söderberg et al. (2012) compared the effect of combined low-dose transpupillary thermotherapy (TTT) and intravitreal ranibizumab with sham TTT and intravitreal ranibizumab in patients with neovascular age-related macular degeneration (AMD). A total of 100 patients were randomly assigned (1:1) to receive intravitreal ranibizumab and sham TTT or intravitreal ranibizumab and low-dose TTT. Patients in the TTT group required fewer treatments with ranibizumab compared to those in the sham TTT group. The mean number of ranibizumab injections was 8.0 in the sham TTT group versus 6.3 in the TTT group over two years. There was no statistically significant difference in best corrected visual acuity (BCVA), central retinal thickness (CRT) or lesion area between the treatment groups at the final examination. The results of the intent-to-treat population (92 patients) were similar to the per-protocol (PP) population. The authors concluded that treatment with low-dose TTT significantly reduced the number of intravitreal injections of ranibizumab over 24 months. According to the authors, these results suggest that low-dose TTT can serve as an adjuvant in combination with intravitreal ranibizumab for neovascular AMD. Further research with a larger number of patients is needed to confirm these results.

In a prospective, interventional, comparative case series, Nowak et al. (2012) compared the efficacy of verteporfin photodynamic therapy (PDT), intravitreal injections of bevacizumab (IVB), and transpupillary thermotherapy (TTT) in patients with neovascular age-related macular degeneration (AMD). The study included 426 eyes of 426 consecutive patients presenting with neovascular AMD. Patients presented with subfoveal CNV predominantly classic, minimally classic, and occult with no classic component; lesion size less than 5000 μm in the greatest linear dimension, and the area of hemorrhages ≤1/3 were randomized to receive either PDT (group I) or IVB (group II) in a 1:1 ratio. Other patients with CNV were included into the group III and received TTT. One hundred eyes were treated with PDT. Mean baseline logMAR BCVA was 0.62 and final visual acuity decreased to 0.74; 104 eyes were treated with IVB. Mean baseline BCVA was 0.82 and final visual acuity increased to 0.79; 222 patients were treated with TTT. Mean baseline BCVA was 1.10 and final visual acuity decreased to 1.15. Among all eyes the average number of treatment sessions was 2.34. The authors concluded that IVB injections had the best efficacy in the improvement of final BCVA. However, both IVB and TTT demonstrated good stabilization of vision. The lack of a control group limits the validity of the results of this study.

Mitamura et al. (2009) compared the therapeutic efficacy of photodynamic therapy (PDT) to that of transpupillary thermotherapy (TTT) for polypoidal choroidal vasculopathy (PCV) a form of choroidal neovascularization. PDT or TTT was performed on 46 eyes of 46 patients with PCV; 19 eyes were treated with TTT (TTT group) and 27 eyes with PDT (PDT group). Best-corrected visual acuity (BCVA) was significantly better and the fovea was significantly thinner in the PDT group than in the TTT group after treatment.

The National Institute for Health and Care Excellence (NICE) concluded that clinical evidence on the safety and efficacy of TTT for age-related macular degeneration was inadequate for TTT to be used without special arrangement for consent and for audit or research (NICE 2004).
**Professional Societies**

**American Academy of Ophthalmology (AAO)**

The AAO preferred practice pattern document for age-related macular degeneration does not address transpupillary thermal therapy (AAO, 2015).

**U.S. FOOD AND DRUG ADMINISTRATION (FDA)**

Ophthalmic lasers are regulated by the FDA as Class II devices and many lasers have been approved via the 510(k) approval process. Ophthalmic diode laser systems that have received 510(k) marketing clearance for transpupillary thermotherapy include but are not limited to:

- IRIS Medical IQ 810 laser photocoagulator (IRIDEX Corp.) 510(k) approval (K040209) received 1/30/2004. (See the following website for more information: [http://www.accessdata.fda.gov/cdrh_docs/pdf4/K040209.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf4/K040209.pdf). (Accessed June 2017)


A listing of all devices in the same product classification as those above (Product Code HQF and GEX) is available on the following FDA Website: [http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm) (Accessed June 2017)

**APPLICABLE CODES**

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the enrollee specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>67299</td>
<td>Unlisted procedure, posterior segment</td>
</tr>
<tr>
<td>92499</td>
<td>Unlisted ophthalmological service or procedure</td>
</tr>
</tbody>
</table>

*CPT® is a registered trademark of the American Medical Association*

**REFERENCES**


**PROTOCOL HISTORY/REVISION INFORMATION**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/22/2017</td>
<td></td>
</tr>
<tr>
<td>06/23/2016</td>
<td>Corporate Medical Affairs Committee</td>
</tr>
<tr>
<td>07/23/2015</td>
<td></td>
</tr>
</tbody>
</table>
The foregoing Health Plan of Nevada/Sierra Health & Life Health Operations protocol has been adopted from an existing UnitedHealthcare coverage determination guideline that was researched, developed and approved by the UnitedHealthcare Coverage Determination Committee.